富康集团创建于1993年，主要从事医药制剂、原料药、热敏材料等六大板块八十多个产品的研发、生产和销售，下辖富康制药、瑞康精化、永康化学、博康制药、内蒙古欣皓医药等九大子公司，已成为20多家世界顶级制药企业的重点供应商。集团公司2024年实现销售收入約10亿美元，争取到2030年实现15亿美元的销售目标。集团公司先后通过了5次美国FDA认证、5次欧盟认证、2次世界卫生组织，2次日本PMDA，2次澳大利亚TGA，一次巴西ANVISA，一次墨西哥COFEPRIS等国际权威质量认证，产品覆盖国内27个省市，畅销美国、加拿大，俄罗斯，法国，西班牙，德国、英国，波兰，捷克，意大利，日本，印度尼西亚，马来西亚，墨西哥，巴西等80多个国家和地区。主导产品双胍（CAS NO.: 1115-70-4）、甲氧苄啶、奥美拉唑、氯氮平，间苯三酚，热敏染料FB2C的产销量居全球首位，国内市场份额均在70%以上；新诺明、氯氮平，埃索镁等品种产销量居全国首位。双胍缓释片、吡格列酮双胍片、间苯三酚注射液、泮托拉唑钠肠溶片、复方新诺明片等19个制剂品种已上市销售，具备注射液、冻干粉针剂、片剂、颗粒剂、胶囊剂等多种剂型以及配套原料药的生产能力，建立起了以双胍为代表的六条完整清晰全产业链。先后跻身“中国医药工业百强”“中国医药企业国际化百强”“山东省‘十强’产业集群领军企业”“潍坊市财税贡献50强企业”行列，获得国家高新技术企业、国家知识产权优势企业、山东省引进高层次人才重点支持企业、潍坊市突出贡献企业等荣誉。Founded in 1993, Fukang Group is primarily engaged in the R&D, production, and sales of over 80 products across six major sectors, including FDFs, APIs, thermosensitive new materials and so on. Fukang Group comprises nine subsidiaries, including Fukang Pharmaceutical Co., Ltd, Ruikang specialty Chemicals Co., Ltd, Yongkang Chemical Industry Co., Ltd, Bokang Pharmaceutical Co.,Ltd, and Inner Mongolia Xinhao Pharmaceutical Technology Co.,Ltd, and has become a key supplier to more than 20 of the world’s top pharmaceutical companies.Fukang Group achieved sales revenue of approximately $1 billion In 2024 and aims to reach a sales target of $1.5 billion by 2030. The group has passed U.S. FDA certification(5 times), EU certification(5 times), WHO certification(2 times), Japan PMDA certification(2 times), Australia TGA certification(2 times), Brazil ANVISA certification(1 time), and Mexico COFEPRIS certification(1 time), among other international quality certifications. Its products are distributed across 27 provinces in China and exported to over 80 countries and regions, including the United States, Canada, Russia, France, Spain, Germany, the UK, Poland, the Czech Republic, Italy, Japan, Indonesia, Malaysia, Mexico, and Brazil.The leading products—Metformin Hydrochloride, Trimethoprim, Omeprazole, Clozapine, Phloroglucinol, and FB2C—rank first globally in production and sales volume, each holding over 70% of the domestic market share. Other products—Sulfamethoxazole, Clozapine, and Esomeprazole Magnesium—also rank first in China in production and sales volume. Nineteen formulation products, including Metformin Hydrochloride Extended-release Tablets, Pioglitazone and Metformin Tablets, Phloroglucinol Injection, Pantoprazole Sodium Enteric-coated Tablets, and Compound Sulfamethoxazole Tablets, have been launched and are commercially available. The Group possesses production capabilities for various dosage forms, such as injections, lyophilized powder injections, tablets, granules, and capsules, along with supporting APIs. It has established six complete and well-defined industrial chains, with metformin as a representative example.Fukang Group has been recognized among "China’s Top 100 Pharmaceutical Enterprises", "China’s Top 100 Internationalized Pharmaceutical Enterprises", "Shandong Province’s Top 10 Industrial Cluster Leading Enterprises" and "Weifang’s Top 50 Tax Contributors". It has also received honors such as National High-Tech Enterprise, National Intellectual Property Advantage Enterprise, Shandong Province Key Enterprise for High-Level Talent Recruitment, and Weifang Outstanding Contribution Enterprise.
